e-journal

De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin

---

In order to develop more effective therapeutic vaccines against cancers with high-risk human papillomavirus
(HPV) infection, it is crucial to enhance the immunogenicity, eliminate the oncogenicity of oncoproteins, and take a combination of E7- and E6-containing vaccines. It has been shown recently that PE(DIII)-E7-KDEL3 (E7), a fusion protein containing the HPV16 oncoprotein E7 and the translocation domain of Pseudomonas aeruginosa exotoxin A, is effective against TC-1 tumor cells inoculated in mice, therefore, we engineered PE(DIII)-E6-CRL-KDEL3 (E6), the deoncogenic versions of the E7 and E6 fusion proteins [i.e.PE(DIII)-E7(d)-KDEL3, E7(d), and PE(DIII)-E6(d)-CRLKDEL3, E6(d)] and tested the immunoefficacies of these fusion proteins as mono- and bivalent vaccines. Results indicated that the E7(d) get higher immunogenicity than its wild type and the E6 fusion proteins augmented the immunogenicity and antitumor effects of their E7 counterparts. Furthermore, the bivalent vaccine system E7(d) plus E6(d), in the presence of cisplatin, showed the best tumoristatic and tumoricidal effects against established tumors in vivo. Therefore, it can be concluded that this novel therapeutic vaccine system, upon further optimization, may shed new light on clinical management of HPV-related carcinomas.

Keywords cancer vaccine; papillomavirus E7 protein; papillomavirus E6 protein; cisplatin; uterine cervical neoplasms

---

Ketersediaan

Tidak ada salinan data

Informasi Detail

Judul Seri

Acta Biochim Biophys Sin

No. Panggil

-

Penerbit

: ., 2014

Deskripsi Fisik

Acta Biochim Biophys Sin 2014, 46: 6–14

Bahasa

English

ISBN/ISSN

-

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

FISIKA

Info Detail Spesifik

-

Pernyataan Tanggungjawab

agus

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar